ADARB2: A Potential Drug Target and Biomarker for Adenosine Deaminase RNA Specific B2

Target Name: ADARB2

NCBI ID: G105

ADARB2

ADARB2: A Potential Drug Target and Biomarker for Adenosine Deaminase RNA Specific B2

Abstract:

Adenosine deaminase (ADAM) is a enzyme involved in the regulation of DNA methylation, which has crucial implications for various cellular processes, including cancer, neurodegenerative diseases, and autoimmune disorders. The RNA-specific B2 (ADARB2) gene has been identified as a potential drug target and biomarker for ADAM. This article will discuss the current understanding of ADARB2 and its potential as a drug target, as well as its potential as a biomarker for various diseases.

Introduction:

Adenosine deaminase (ADAM) is an enzyme that plays a critical role in the regulation of DNA methylation, a process that involves the addition of an amino acid to the methylation cap of a DNA strand. Methylation of the promoter region of a gene can either activate or repress its expression. ADAM is involved in the addition of the amino acid Lys(205) to the methylation cap, thereby allowing the gene to be transcribed and translated into protein.

ADARB2: A Potential Drug Target:

The ADARB2 gene has been identified as a potential drug target for ADAM. ADARB2 is a 21-kDa RNA-specific B2 enzyme that is highly conserved across various species, including humans. It is expressed in various tissues, including brain, heart, liver, and muscle. Several studies have shown that ADARB2 is involved in the regulation of gene expression and has been implicated in various cellular processes, including cell growth, apoptosis, and inflammation.

One of the key features of ADARB2 is its specificity for the RNA-specific B2 subunit. This specificity makes ADARB2 a potential drug target for ADAM, as ADAM is the primary enzyme responsible for the addition of the Lys(205) amino acid to the methylation cap of RNA strands. By inhibiting the activity of ADARB2, researchers can study the effects of ADAM on gene expression and potentially identify new drug targets for cancer, neurodegenerative diseases, and autoimmune disorders.

ADARB2 as a Biomarker:

ADARB2 has also been identified as a potential biomarker for various diseases. For example, several studies have shown that ADARB2 is downregulated in various tissues and diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This downregulation has been attributed to various mechanisms, including changes in gene expression, DNA methylation, and protein levels.

One of the key applications of ADARB2 as a biomarker is its potential to identify new biomarkers for disease. By studying the expression and activity of ADARB2, researchers can identify new targets for drugs that target this enzyme and potentially develop new diagnostic tools for diseases associated with ADARB2 dysfunction.

Conclusion:

ADARB2 is a gene that has been identified as a potential drug target for ADAM and has the potential to serve as a biomarker for various diseases. Further research is needed to fully understand the role of ADARB2 in gene expression and its potential as a drug target and biomarker. By studying the effects of inhibiting the activity of ADARB2, researchers can identify new therapeutic strategies for cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: Adenosine Deaminase RNA Specific B2 (inactive)

Functions: Lacks editing activity. It prevents the binding of other ADAR enzymes to targets in vitro, and decreases the efficiency of these enzymes. Capable of binding to dsRNA but also to ssRNA

The "ADARB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADARB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets